In short
Telisotuzumab Vedotin, also known as ABBV-399, is an investigational drug being studied in clinical trials for the treatment of non-small cell lung cancer (NSCLC). This article explores the ongoing research on Telisotuzumab Vedotin, its potential benefits, and its role in addressing specific types of NSCLC, particularly those overexpressing the c-Met protein. The trials aim to assess the drug's safety, efficacy, and potential combinations with other treatments to improve outcomes for patients with advanced NSCLC.
At a glance
- Drug Name
- Telisotuzumab Vedotin (ABBV-399)
- Type of Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Target Population
- Patients with c-Met overexpressing NSCLC, including those with EGFR mutations
- Administration
- Intravenous (IV) infusion
- Trial Phases
- Phase 1, 2, and 3 studies ongoing
- Key Objectives
- Safety, efficacy, pharmacokinetics, progression-free survival, overall survival
- Combination Therapies
- Studied with osimertinib, erlotinib, nivolumab, and standard chemotherapy
- Primary Outcomes
- Adverse events, response rates, progression-free survival
- Secondary Outcomes
- Duration of response, disease control rate, overall survival, quality of life measures
- Special Considerations
- Monitoring for interstitial lung disease, peripheral neuropathy, ocular surface disorders
What is Telisotuzumab Vedotin?
Telisotuzumab Vedotin, also known as ABBV-399, is an investigational drug being developed for the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called antibody-drug conjugates, which are designed to target and kill cancer cells more precisely than traditional chemotherapy.
How Does It Work?
Telisotuzumab Vedotin works by targeting a specific protein called c-Met, which is often overexpressed in certain types of lung cancer. The drug consists of two main parts:
- An antibody that recognizes and binds to c-Met on cancer cells
- A potent anti-cancer drug (vedotin) attached to the antibody
When Telisotuzumab Vedotin binds to c-Met on cancer cells, it delivers the vedotin directly to these cells, potentially killing them while minimizing damage to healthy cells.
What Conditions Does It Treat?
Telisotuzumab Vedotin is primarily being studied for the treatment of non-small cell lung cancer (NSCLC). Specifically, it is being investigated for patients with:
- Advanced or metastatic NSCLC (cancer that has spread to other parts of the body)
- NSCLC that overexpresses the c-Met protein
- NSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene
- NSCLC that has progressed after previous treatments
Some studies are also exploring its use in other advanced solid tumors that express c-Met.
Current Research and Clinical Trials
Several clinical trials are currently underway to evaluate the safety and effectiveness of Telisotuzumab Vedotin:
- Phase 2 studies are assessing its use as a single agent in previously treated NSCLC patients.
- A Phase 3 study is comparing Telisotuzumab Vedotin combined with osimertinib (another lung cancer drug) to standard chemotherapy in patients with EGFR-mutant, c-Met overexpressing NSCLC.
- Other studies are exploring different dosing regimens and combinations with other cancer drugs.
These trials aim to determine the optimal use of Telisotuzumab Vedotin and identify which patients are most likely to benefit from the treatment.
Administration and Dosing
Telisotuzumab Vedotin is administered as an intravenous (IV) infusion, which means it is given directly into a vein. The dosing schedule varies depending on the specific clinical trial, but some common regimens include:
- Every 14 days (2 weeks) on a 28-day cycle
- Every 21 days (3 weeks)
The exact dose and schedule may be adjusted based on how well a patient tolerates the treatment and their individual response.
Potential Side Effects
As with any cancer treatment, Telisotuzumab Vedotin may cause side effects. Some potential side effects being monitored in clinical trials include:
- Interstitial lung disease (ILD): A group of lung disorders that can cause inflammation and scarring of lung tissue
- Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet
- Ocular surface disorders: Problems affecting the surface of the eye
- Other general side effects such as fatigue, nausea, or changes in blood cell counts
It's important to note that not all patients will experience these side effects, and researchers are carefully monitoring patients to understand the safety profile of the drug.
Future Prospects
Telisotuzumab Vedotin shows promise as a potential new treatment option for certain types of non-small cell lung cancer, particularly those that overexpress the c-Met protein. Ongoing research aims to:
- Determine its effectiveness compared to standard treatments
- Identify which patients are most likely to benefit from the drug
- Explore combinations with other cancer therapies to potentially improve outcomes
While Telisotuzumab Vedotin is still considered an investigational drug, early results have been encouraging enough to warrant further study. Patients interested in learning more about this treatment should discuss it with their oncologist to see if they might be eligible for any ongoing clinical trials.